{"id":"NCT01463683","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)","officialTitle":"A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-29","primaryCompletion":"2012-11-06","completion":"2012-11-06","firstPosted":"2011-11-02","resultsPosted":"2014-02-17","lastUpdate":"2018-07-18"},"enrollment":722,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"2XP HEPTAVAX™-II SC","otherNames":["RECOMBIVAX HB","HBVAXPRO"]},{"type":"BIOLOGICAL","name":"1XP HEPTAVAX™-II SC","otherNames":["RECOMBIVAX HB","HBVAXPRO"]},{"type":"BIOLOGICAL","name":"2XP HEPTAVAX™-II IM","otherNames":[]}],"arms":[{"label":"V232-2XP SC","type":"EXPERIMENTAL"},{"label":"V232-1XP SC","type":"ACTIVE_COMPARATOR"},{"label":"V232-2XP IM","type":"EXPERIMENTAL"}],"summary":"This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.","primaryOutcome":{"measure":"Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection","timeFrame":"Month 7","effectByArm":[{"arm":"V232-2XP SC","deltaMin":90.1,"sd":null},{"arm":"V232-1XP SC","deltaMin":82.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29553862"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":309},"commonTop":["Injection-site pain","Injection-site erythema","Injection-site swelling","Injection-site pruritus","Headache"]}}